North American Erbitux Sales Up 17 Percent In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.
You may also be interested in...
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.
Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says
In contrast to Lilly, Bristol management says it expects FDA to schedule an advisory committee review for the Plavix competitor.